Date. 12/06/2023
In this conversation on OncologyTube, viewers can explore the SWOG 18 clinical trial with host Allen Wilbanks and Dr. Anjali Advani, a medical oncologist and professor at the Cleveland Clinic. The discussion centers on the long-term follow-up data of combining dasatinib, prednisone, and blinatumomab for the treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) in older patients.
Dr. Advani, the director of the inpatient leukemia program at the Cleveland Clinic, provides insights into the eligibility criteria for the study, specifically focusing on older patients with Ph+ ALL. The conversation delves into the treatment protocol’s feasibility and safety aspects, addressing challenges encountered during post-induction courses of treatment.
The dialogue progresses to the significance of achieving complete remission during dasatinib and prednisone induction therapy. Dr. Advani explains the role of minimal residual disease assessment in evaluating treatment response and predicting outcomes, offering a pragmatic perspective on managing Ph+ ALL in older patient populations.
The discussion extends to the long-term outcomes observed in the trial, including survival rates and factors associated with relapse. Dr. Advani provides a factual overview of the results, emphasizing overall survival and median free survival without embellishing the findings.
Wrapping up, Dr. Advani touches upon the incorporation of maintenance therapy with prednisone and dasatinib, outlining the rationale behind this approach and its role in enhancing the durability of treatment response. This conversation provides a factual exploration of the evolving landscape of treating Ph+ ALL in older patient demographics